KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Operations (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Cash from Operations for 11 consecutive years, with 92553000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 84.99% to 92553000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 345014000.0 through Dec 2025, down 141.65% year-over-year, with the annual reading at 345014000.0 for FY2025, 141.65% down from the prior year.
  • Cash from Operations hit 92553000.0 in Q4 2025 for CRISPR Therapeutics AG, down from 84634000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 807002000.0 in Q2 2021 to a low of 141956000.0 in Q2 2022.
  • Historically, Cash from Operations has averaged 35246600.0 across 5 years, with a median of 94067500.0 in 2024.
  • Biggest five-year swings in Cash from Operations: soared 2856.25% in 2021 and later tumbled 168.25% in 2024.
  • Year by year, Cash from Operations stood at 86038000.0 in 2021, then crashed by 31.72% to 113328000.0 in 2022, then grew by 15.23% to 96073000.0 in 2023, then soared by 47.92% to 50031000.0 in 2024, then crashed by 84.99% to 92553000.0 in 2025.
  • Business Quant data shows Cash from Operations for CRSP at 92553000.0 in Q4 2025, 84634000.0 in Q3 2025, and 113880000.0 in Q2 2025.